Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	linoleic acid epoxygenase activity	CYP2C19 CYP2C9 CYP2C18	1.95e-07	4	74	3	GO:0071614
GeneOntologyMolecularFunction	(R)-limonene 6-monooxygenase activity	CYP2C19 CYP2C9	1.35e-05	2	74	2	GO:0052741
GeneOntologyMolecularFunction	limonene monooxygenase activity	CYP2C19 CYP2C9	1.35e-05	2	74	2	GO:0019113
GeneOntologyMolecularFunction	(S)-limonene 6-monooxygenase activity	CYP2C19 CYP2C9	1.35e-05	2	74	2	GO:0018675
GeneOntologyMolecularFunction	(S)-limonene 7-monooxygenase activity	CYP2C19 CYP2C9	1.35e-05	2	74	2	GO:0018676
GeneOntologyMolecularFunction	neutral L-amino acid transmembrane transporter activity	SLC7A8 SLC6A7 SLC43A1 MFSD12	1.59e-05	41	74	4	GO:0015175
GeneOntologyMolecularFunction	retinoic acid 4-hydroxylase activity	CYP2C19 CYP2C9 CYP2C18	1.73e-05	14	74	3	GO:0008401
GeneOntologyMolecularFunction	arachidonate 11,12-epoxygenase activity	CYP2C19 CYP2C9	8.09e-05	4	74	2	GO:0008405
GeneOntologyMolecularFunction	arachidonate epoxygenase activity	CYP2C19 CYP2C9 CYP2C18	9.35e-05	24	74	3	GO:0008392
GeneOntologyMolecularFunction	arachidonate monooxygenase activity	CYP2C19 CYP2C9 CYP2C18	1.34e-04	27	74	3	GO:0008391
GeneOntologyMolecularFunction	fatty acid omega-1 hydroxylase activity	CYP2C19 CYP2C9	1.35e-04	5	74	2	GO:0120502
GeneOntologyMolecularFunction	long-chain fatty acid omega-1 hydroxylase activity	CYP2C19 CYP2C9	1.35e-04	5	74	2	GO:0120319
GeneOntologyMolecularFunction	arachidonate 14,15-epoxygenase activity	CYP2C19 CYP2C9	1.35e-04	5	74	2	GO:0008404
GeneOntologyMolecularFunction	L-leucine transmembrane transporter activity	SLC7A8 SLC43A1	2.01e-04	6	74	2	GO:0015190
GeneOntologyMolecularFunction	organic cation transmembrane transporter activity	SLC7A8 SLC6A7 SLC43A1 MFSD12	2.56e-04	83	74	4	GO:0015101
GeneOntologyMolecularFunction	aromatase activity	CYP2C19 CYP2C9 CYP2C18	2.94e-04	35	74	3	GO:0070330
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor	CYP2C19 CYP2C9	3.74e-04	8	74	2	GO:0033695
GeneOntologyMolecularFunction	caffeine oxidase activity	CYP2C19 CYP2C9	3.74e-04	8	74	2	GO:0034875
GeneOntologyMolecularFunction	G protein-coupled receptor activity	NPBWR1 CXCR3 OR1B1 P2RY6 MAS1 MRGPRE MRGPRX4 GPRC5D OR1J4 OR1J2 ADGRL4	3.92e-04	884	74	11	GO:0004930
GeneOntologyMolecularFunction	transmembrane signaling receptor activity	NPBWR1 CXCR3 FLT1 OR1B1 P2RY6 MAS1 MRGPRE MRGPRX4 GPRC5D FGFR1 OR1J4 OR1J2 ADGRL4 EPHA5	3.94e-04	1353	74	14	GO:0004888
GeneOntologyMolecularFunction	branched-chain amino acid transmembrane transporter activity	SLC7A8 SLC43A1	5.98e-04	10	74	2	GO:0015658
GeneOntologyMolecularFunction	amino acid transmembrane transporter activity	SLC7A8 SLC6A7 SLC43A1 MFSD12	6.26e-04	105	74	4	GO:0015171
GeneOntologyMolecularFunction	estrogen 16-alpha-hydroxylase activity	CYP2C19 CYP2C9	7.29e-04	11	74	2	GO:0101020
GeneOntologyMolecularFunction	organic anion transmembrane transporter activity	SLC7A8 SLC6A7 SLC52A1 SLC43A1 SLC22A10 MFSD12	7.61e-04	293	74	6	GO:0008514
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	CYP2C19 CYP2C9 CYP2C18	7.96e-04	49	74	3	GO:0016712
GeneOntologyMolecularFunction	toxin transmembrane transporter activity	SLC7A8 SLC22A10	8.73e-04	12	74	2	GO:0019534
GeneOntologyMolecularFunction	carboxylic acid transmembrane transporter activity	SLC7A8 SLC6A7 SLC43A1 SLC22A10 MFSD12	1.03e-03	207	74	5	GO:0046943
GeneOntologyMolecularFunction	organic acid transmembrane transporter activity	SLC7A8 SLC6A7 SLC43A1 SLC22A10 MFSD12	1.05e-03	208	74	5	GO:0005342
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups	CYP2C19 CYP2C9	1.38e-03	15	74	2	GO:0016725
GeneOntologyMolecularFunction	transmembrane receptor protein tyrosine kinase activity	FLT1 FGFR1 EPHA5	1.81e-03	65	74	3	GO:0004714
GeneOntologyMolecularFunction	L-amino acid transmembrane transporter activity	SLC7A8 SLC6A7 SLC43A1	2.33e-03	71	74	3	GO:0015179
GeneOntologyMolecularFunction	ubiquitin-specific protease binding	AMFR MARCHF6	2.47e-03	20	74	2	GO:1990381
GeneOntologyMolecularFunction	heme binding	DUOX1 CYP2C19 CYP2C9 CYP2C18	2.58e-03	154	74	4	GO:0020037
GeneOntologyMolecularFunction	tetrapyrrole binding	DUOX1 CYP2C19 CYP2C9 CYP2C18	3.23e-03	164	74	4	GO:0046906
GeneOntologyMolecularFunction	transmembrane receptor protein kinase activity	FLT1 FGFR1 EPHA5	3.88e-03	85	74	3	GO:0019199
GeneOntologyMolecularFunction	protease binding	AMFR MARCHF6 CNTNAP2 PINK1	4.59e-03	181	74	4	GO:0002020
GeneOntologyMolecularFunction	secondary active transmembrane transporter activity	SLC7A8 SLC6A7 SLC22A10 SLC35E4 MFSD12	4.84e-03	296	74	5	GO:0015291
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	CYP2C19 CYP2C9 CYP2C18 KDM2B	5.85e-03	194	74	4	GO:0016705
GeneOntologyMolecularFunction	peptide binding	SLC7A8 CACNA1B NPBWR1 MAS1 MRGPRX4	6.53e-03	318	74	5	GO:0042277
GeneOntologyMolecularFunction	steroid hydroxylase activity	CYP2C19 CYP2C9	7.04e-03	34	74	2	GO:0008395
GeneOntologyMolecularFunction	oxygen binding	CYP2C19 CYP2C18	8.30e-03	37	74	2	GO:0019825
GeneOntologyMolecularFunction	neuropeptide binding	NPBWR1 MRGPRX4	8.30e-03	37	74	2	GO:0042923
GeneOntologyBiologicalProcess	neutral amino acid transport	SLC7A8 SLC6A7 SLC43A1 MFSD12	6.06e-05	60	73	4	GO:0015804
GeneOntologyBiologicalProcess	epoxygenase P450 pathway	CYP2C19 CYP2C9 CYP2C18	6.24e-05	22	73	3	GO:0019373
GeneOntologyBiologicalProcess	linoleic acid metabolic process	CYP2C19 CYP2C9 CYP2C18	7.16e-05	23	73	3	GO:0043651
GeneOntologyBiologicalProcess	valine transport	SLC7A8 SLC43A1	7.38e-05	4	73	2	GO:0015829
GeneOntologyBiologicalProcess	organic hydroxy compound metabolic process	SGPP1 DUOX1 CYP2C9 ERG28 CYP2C18 P2RY6 MAS1 FGFR1 CDH3 MFSD12	8.34e-05	641	73	10	GO:1901615
GeneOntologyBiologicalProcess	L-leucine import across plasma membrane	SLC7A8 SLC43A1	1.23e-04	5	73	2	GO:1903801
GeneOntologyBiologicalProcess	monoterpenoid metabolic process	CYP2C19 CYP2C9	1.84e-04	6	73	2	GO:0016098
GeneOntologyBiologicalProcess	response to odorant	CNTNAP2 CFAP69	1.84e-04	6	73	2	GO:1990834
GeneOntologyCellularComponent	endoplasmic reticulum membrane	SGPP1 AMFR CYP2C19 CYP2C9 ERG28 CYP2C18 SGMS1 SLC43A1 MARCHF6 PIGW DCSTAMP TMEM86A CLCC1	5.57e-04	1293	74	13	GO:0005789
GeneOntologyCellularComponent	endoplasmic reticulum subcompartment	SGPP1 AMFR CYP2C19 CYP2C9 ERG28 CYP2C18 SGMS1 SLC43A1 MARCHF6 PIGW DCSTAMP TMEM86A CLCC1	5.82e-04	1299	74	13	GO:0098827
GeneOntologyCellularComponent	nuclear outer membrane-endoplasmic reticulum membrane network	SGPP1 AMFR CYP2C19 CYP2C9 ERG28 CYP2C18 SGMS1 SLC43A1 MARCHF6 PIGW DCSTAMP TMEM86A CLCC1	7.11e-04	1327	74	13	GO:0042175
Domain	MRGPCRFAMILY	MAS1 MRGPRE MRGPRX4	9.63e-06	11	74	3	IPR026234
Domain	Cyt_P450_E_grp-I	CYP2C19 CYP2C9 CYP2C18	7.52e-04	45	74	3	IPR002401
Domain	Cyt_P450_CS	CYP2C19 CYP2C9 CYP2C18	1.21e-03	53	74	3	IPR017972
Domain	GPCR_Rhodpsn_7TM	NPBWR1 CXCR3 OR1B1 P2RY6 MAS1 MRGPRE MRGPRX4 OR1J4 OR1J2	1.29e-03	670	74	9	IPR017452
Domain	7tm_1	NPBWR1 CXCR3 OR1B1 P2RY6 MAS1 MRGPRE MRGPRX4 OR1J4 OR1J2	1.38e-03	677	74	9	PF00001
Domain	CYTOCHROME_P450	CYP2C19 CYP2C9 CYP2C18	1.50e-03	57	74	3	PS00086
Domain	G_PROTEIN_RECEP_F1_1	NPBWR1 CXCR3 OR1B1 P2RY6 MAS1 MRGPRE MRGPRX4 OR1J4 OR1J2	1.50e-03	685	74	9	PS00237
Domain	-	CYP2C19 CYP2C9 CYP2C18	1.58e-03	58	74	3	1.10.630.10
Domain	p450	CYP2C19 CYP2C9 CYP2C18	1.58e-03	58	74	3	PF00067
Domain	G_PROTEIN_RECEP_F1_2	NPBWR1 CXCR3 OR1B1 P2RY6 MAS1 MRGPRE MRGPRX4 OR1J4 OR1J2	1.59e-03	691	74	9	PS50262
Domain	GPCR_Rhodpsn	NPBWR1 CXCR3 OR1B1 P2RY6 MAS1 MRGPRE MRGPRX4 OR1J4 OR1J2	1.61e-03	692	74	9	IPR000276
Domain	Cyt_P450	CYP2C19 CYP2C9 CYP2C18	1.74e-03	60	74	3	IPR001128
Domain	MFS_dom	SLC43A1 SLC22A10 MFSD6L MFSD12	1.98e-03	134	74	4	IPR020846
Domain	SAM_1	SGMS1 SCMH1 EPHA5	2.49e-03	68	74	3	PF00536
Domain	P_Acid_Pase_2/haloperoxidase	SGPP1 SGMS1	2.81e-03	20	74	2	IPR000326
Domain	PAP2	SGPP1 SGMS1	2.81e-03	20	74	2	PF01569
Domain	MFS_1	SLC43A1 SLC22A10 MFSD12	3.54e-03	77	74	3	PF07690
Domain	MFS	SLC43A1 SLC22A10 MFSD12	3.54e-03	77	74	3	IPR011701
Domain	TyrKc	FLT1 FGFR1 EPHA5	5.15e-03	88	74	3	SM00219
Domain	Tyr_kinase_cat_dom	FLT1 FGFR1 EPHA5	5.15e-03	88	74	3	IPR020635
Pathway	WP_EICOSANOID_METABOLISM_VIA_CYTOCHROME_P450_MONOOXYGENASES	CYP2C19 CYP2C9 CYP2C18	1.88e-05	14	54	3	MM15842
Pathway	REACTOME_XENOBIOTICS	CYP2C19 CYP2C9 CYP2C18	8.91e-05	23	54	3	M5372
Pathway	KEGG_LINOLEIC_ACID_METABOLISM	CYP2C19 CYP2C9 CYP2C18	1.81e-04	29	54	3	M2920
Pubmed	Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities.	CYP2C19 CYP2C9 CYP2C18	9.25e-09	3	74	3	15102943
Pubmed	Cloning and expression of complementary DNAs for multiple members of the human cytochrome PH50IIC subfamily.	CYP2C19 CYP2C9 CYP2C18	9.25e-09	3	74	3	8095407
Pubmed	Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.	CYP2C19 CYP2C9 CYP2C18	3.69e-08	4	74	3	2009263
Pubmed	Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population.	CYP2C19 CYP2C9 CYP2C18	3.69e-08	4	74	3	21798861
Pubmed	Biochemistry and molecular biology of the human CYP2C subfamily.	CYP2C19 CYP2C9 CYP2C18	3.69e-08	4	74	3	7704034
Pubmed	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.	CYP2C19 CYP2C9 CYP2C18	3.69e-08	4	74	3	23755828
Pubmed	Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.	CYP2C19 CYP2C9 CYP2C18	3.69e-08	4	74	3	19706858
Pubmed	A genome-wide association study of acenocoumarol maintenance dosage.	CYP2C19 CYP2C9 CYP2C18	1.84e-07	6	74	3	19578179
Pubmed	Comparative genomic analysis of eutherian Mas-related G protein-coupled receptor genes.	MAS1 MRGPRE MRGPRX4	5.14e-07	8	74	3	24583173
Pubmed	Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population.	CYP2C19 CYP2C9 CYP2C18	3.31e-06	14	74	3	19290787
Pubmed	CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.	CYP2C19 CYP2C9	4.47e-06	2	74	2	16198656
Pubmed	[Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].	CYP2C19 CYP2C9	4.47e-06	2	74	2	15569425
Pubmed	Important amino acid residues that confer CYP2C19 selective activity to CYP2C9.	CYP2C19 CYP2C9	4.47e-06	2	74	2	18511451
Pubmed	Developmental expression of human hepatic CYP2C9 and CYP2C19.	CYP2C19 CYP2C9	4.47e-06	2	74	2	14634042
Pubmed	Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines.	CYP2C9 CYP2C18	4.47e-06	2	74	2	22918969
Pubmed	An association between the rs1799853 and rs1057910 polymorphisms of CYP2C9, the rs4244285 polymorphism of CYP2C19 and the prevalence rates of drug-resistant epilepsy in children.	CYP2C19 CYP2C9	4.47e-06	2	74	2	32567426
Pubmed	CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract.	CYP2C19 CYP2C9	4.47e-06	2	74	2	10908295
Pubmed	Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis.	CYP2C19 CYP2C9	4.47e-06	2	74	2	17868191
Pubmed	Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.	CYP2C19 CYP2C9	4.47e-06	2	74	2	32868386
Pubmed	CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.	CYP2C19 CYP2C9	4.47e-06	2	74	2	27617498
Pubmed	Oxygenation mechanism in conversion of aldehyde to carboxylic acid catalyzed by a cytochrome P-450 isozyme.	CYP2C19 CYP2C9	4.47e-06	2	74	2	1847130
Pubmed	Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.	CYP2C19 CYP2C9	4.47e-06	2	74	2	16873909
Pubmed	Cytochromes P450 catalyze oxidation of alpha,beta-unsaturated aldehydes.	CYP2C19 CYP2C9	4.47e-06	2	74	2	17599801
Pubmed	Few alterations in clinical pathology and histopathology observed in a CYP2C18&19 humanized mice model.	CYP2C19 CYP2C18	4.47e-06	2	74	2	19038035
Pubmed	Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans.	CYP2C19 CYP2C18	4.47e-06	2	74	2	8110777
Pubmed	Comparison of the in vitro mutagenicity and metabolism of dimethylnitrosamine and benzo[a]pyrene in tissues from inbred mice treated with phenobarbital, 3-methylcholanthrene or polychlorinated biphenyls.	CYP2C19 CYP2C9	4.47e-06	2	74	2	106274
Pubmed	Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.	CYP2C19 CYP2C9	4.47e-06	2	74	2	15385837
Pubmed	[Effect of original and generic clopidogrel on prognosis in relation to different gene polymorphisms].	CYP2C19 CYP2C9	4.47e-06	2	74	2	25518510
Pubmed	Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.	CYP2C9 CYP2C18	4.47e-06	2	74	2	8333835
Pubmed	Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.	CYP2C19 CYP2C9	4.47e-06	2	74	2	15776277
Pubmed	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.	CYP2C19 CYP2C9	4.47e-06	2	74	2	15842554
Pubmed	Effect of cytochrome P450 2C19 and 2C9 amino acid residues 72 and 241 on metabolism of tricyclic antidepressant drugs.	CYP2C19 CYP2C9	4.47e-06	2	74	2	24492587
Pubmed	Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.	CYP2C19 CYP2C9	4.47e-06	2	74	2	19136640
Pubmed	Mouse Cyp2c expression and zonation structure in the liver begins in the early neonatal stage.	CYP2C19 CYP2C9	4.47e-06	2	74	2	35748067
Pubmed	Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.	CYP2C19 CYP2C9	4.47e-06	2	74	2	16232205
Pubmed	Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development.	CYP2C19 CYP2C9	4.47e-06	2	74	2	32587777
Pubmed	Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China.	CYP2C19 CYP2C9	4.47e-06	2	74	2	20845310
Pubmed	Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.	CYP2C19 CYP2C9	4.47e-06	2	74	2	17201743
Pubmed	CYP2C9 (2&3) and CYP2C19 (2&3) polymorphisms among children with nonlesional epilepsy: a single-center study.	CYP2C19 CYP2C9	4.47e-06	2	74	2	32683556
Pubmed	Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients.	CYP2C19 CYP2C9	4.47e-06	2	74	2	15855721
Pubmed	Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid.	CYP2C19 CYP2C9	4.47e-06	2	74	2	9721182
Pubmed	The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects.	CYP2C19 CYP2C9	4.47e-06	2	74	2	19847408
Pubmed	CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.	CYP2C19 CYP2C9	4.47e-06	2	74	2	17504998
Pubmed	Cytochrome P450 2C epoxygenases mediate photochemical stress-induced death of photoreceptors.	CYP2C19 CYP2C9	4.47e-06	2	74	2	24519941
Pubmed	Mouse liver CYP2C39 is a novel retinoic acid 4-hydroxylase. Its down-regulation offers a molecular basis for liver retinoid accumulation and fibrosis in aryl hydrocarbon receptor-null mice.	CYP2C19 CYP2C9	4.47e-06	2	74	2	14623888
Pubmed	Cytochrome P450 polymorphisms in patients with Behcet's disease.	CYP2C19 CYP2C9	4.47e-06	2	74	2	17269966
Pubmed	Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes.	CYP2C19 CYP2C9	4.47e-06	2	74	2	11950794
Pubmed	Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).	CYP2C19 CYP2C9	4.47e-06	2	74	2	17279092
Pubmed	Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis.	CYP2C19 CYP2C9	4.47e-06	2	74	2	22589111
Pubmed	Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.	CYP2C19 CYP2C9	4.47e-06	2	74	2	32216088
Pubmed	cDNA cloning and sequence of CYP2C29 encoding P-450 MUT-2, a microsomal aldehyde oxygenase.	CYP2C19 CYP2C9	4.47e-06	2	74	2	8130255
Pubmed	Membrane integration of recombinant human P450 forms.	CYP2C19 CYP2C9	4.47e-06	2	74	2	19534586
Pubmed	CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.	CYP2C19 CYP2C9	4.47e-06	2	74	2	15660966
Pubmed	Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.	CYP2C19 CYP2C9	4.47e-06	2	74	2	18154472
Pubmed	Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.	CYP2C19 CYP2C9	4.47e-06	2	74	2	27353638
Pubmed	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.	CYP2C19 CYP2C9	4.47e-06	2	74	2	17298483
Pubmed	Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C93 and CYP2C193 Gene Variations With Type 2 Diabetes: A Case-Control Study.	CYP2C19 CYP2C9	4.47e-06	2	74	2	33115391
Pubmed	Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.	CYP2C19 CYP2C9	4.47e-06	2	74	2	17562299
Pubmed	Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant.	CYP2C19 CYP2C9	4.47e-06	2	74	2	36960518
Pubmed	Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.	CYP2C19 CYP2C9	4.47e-06	2	74	2	26690534
Pubmed	Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.	CYP2C19 CYP2C9	4.47e-06	2	74	2	33232775
Pubmed	Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.	CYP2C19 CYP2C9	4.47e-06	2	74	2	19199010
Pubmed	Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.	CYP2C19 CYP2C9	4.47e-06	2	74	2	17304159
Pubmed	Genetic Polymorphisms of CYP2C9/CYP2C19 in Chronic Obstructive Pulmonary Disease.	CYP2C19 CYP2C9	4.47e-06	2	74	2	32757668
Pubmed	A comparative analysis of binding sites between mouse CYP2C38 and CYP2C39 based on homology modeling, molecular dynamics simulation and docking studies.	CYP2C19 CYP2C9	4.47e-06	2	74	2	19358898
Pubmed	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.	CYP2C19 CYP2C9	4.47e-06	2	74	2	20390258
Pubmed	Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians.	CYP2C19 CYP2C9	4.47e-06	2	74	2	19761366
Pubmed	Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.	CYP2C19 CYP2C9	4.47e-06	2	74	2	14616425
Pubmed	Cyp2c-deficiency depletes muricholic acids and protects against high-fat diet-induced obesity in male mice but promotes liver damage.	CYP2C19 CYP2C9	4.47e-06	2	74	2	34438105
Pubmed	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.	CYP2C19 CYP2C9	4.47e-06	2	74	2	12496751
Pubmed	Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.	CYP2C19 CYP2C9	4.47e-06	2	74	2	24403552
Pubmed	Chromosomal organization of the cytochrome P450-2C gene family in the mouse: a locus associated with constitutive aryl hydrocarbon hydroxylase.	CYP2C19 CYP2C9	4.47e-06	2	74	2	2895926
Pubmed	A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram.	CYP2C19 CYP2C18	4.47e-06	2	74	2	33759177
Pubmed	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers.	CYP2C19 CYP2C9	4.47e-06	2	74	2	20831536
Pubmed	Association of warfarin dose with genes involved in its action and metabolism.	CYP2C19 CYP2C9 CYP2C18	5.08e-06	16	74	3	17048007
Pubmed	Molecular genetics of the human cytochrome P450 monooxygenase superfamily.	CYP2C19 CYP2C9 CYP2C18	1.03e-05	20	74	3	9890157
Pubmed	Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.	CYP2C19 CYP2C9	1.34e-05	3	74	2	28687336
Pubmed	CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.	CYP2C19 CYP2C9	1.34e-05	3	74	2	16220110
Pubmed	Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology.	CYP2C19 CYP2C9	1.34e-05	3	74	2	15090156
Pubmed	Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?	CYP2C19 CYP2C9	1.34e-05	3	74	2	19192051
Pubmed	Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran.	CYP2C19 CYP2C9	1.34e-05	3	74	2	20885015
Pubmed	Association of genetic polymorphisms with warfarin dose requirements in Chinese patients.	CYP2C19 CYP2C9	1.34e-05	3	74	2	23941071
Pubmed	CYP2C29 produces superoxide in response to shear stress.	CYP2C19 CYP2C9	1.34e-05	3	74	2	22708815
Pubmed	Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.	CYP2C19 CYP2C9	1.34e-05	3	74	2	17827141
Pubmed	The human CYP2C locus: a prototype for intergenic and exon repetition splicing events.	CYP2C9 CYP2C18	1.34e-05	3	74	2	10704292
Pubmed	Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19.	CYP2C19 CYP2C9	1.34e-05	3	74	2	23834474
Pubmed	A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24.	CYP2C19 CYP2C9	1.34e-05	3	74	2	8530044
Pubmed	Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.	CYP2C19 CYP2C9	1.34e-05	3	74	2	23469989
Pubmed	Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.	CYP2C19 CYP2C9	1.34e-05	3	74	2	21173785
Pubmed	Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH.	CYP2C19 CYP2C9	1.34e-05	3	74	2	38740087
Pubmed	Analysis of CYP2C92, CYP2C192, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus.	CYP2C19 CYP2C9	1.34e-05	3	74	2	21108610
Pubmed	Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.	CYP2C19 CYP2C9	1.34e-05	3	74	2	16236141
Pubmed	The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.	CYP2C19 CYP2C9	1.34e-05	3	74	2	11908757
Pubmed	Genetic expression of aryl hydrocarbon hydroxylase activity in the mouse. Distinction between the "responsive" homozygote and heterozygote at the Ah locus.	CYP2C19 CYP2C9	1.34e-05	3	74	2	1119809
Pubmed	VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.	CYP2C19 CYP2C9	1.34e-05	3	74	2	16890578
Pubmed	Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.	CYP2C19 CYP2C9	1.34e-05	3	74	2	18496682
Pubmed	CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project.	CYP2C19 CYP2C9	1.34e-05	3	74	2	35134542
Pubmed	Characterization of a mouse beta 1-adrenergic receptor genomic clone.	CYP2C19 CYP2C9	1.34e-05	3	74	2	8392347
Pubmed	VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients.	CYP2C19 CYP2C9	1.34e-05	3	74	2	19745563
Pubmed	Complete inhibition of goiter in mice requires combined gene therapy modification of angiopoietin, vascular endothelial growth factor, and fibroblast growth factor signaling.	FLT1 FGFR1	1.34e-05	3	74	2	15817662
Interaction	CYP2C19 interactions	CYP2C19 CYP2C9 CYP2C18	3.50e-07	5	67	3	int:CYP2C19
Cytoband	10q24	CYP2C19 CYP2C9 CYP2C18	2.54e-05	35	74	3	10q24
Cytoband	13q12	FLT1 LHFPL6	6.91e-04	24	74	2	13q12
Cytoband	8q21.3	MMP16 TMEM64	1.01e-03	29	74	2	8q21.3
Cytoband	Ensembl 112 genes in cytogenetic band chr9q33	OR1B1 OR1J4 OR1J2	1.47e-03	138	74	3	chr9q33
Cytoband	9q34.11	OR1J4 OR1J2	3.35e-03	53	74	2	9q34.11
GeneFamily	Cytochrome P450 family 2	CYP2C19 CYP2C9 CYP2C18	1.46e-04	35	53	3	1001
GeneFamily	Olfactory receptors, family 1	OR1B1 OR1J4 OR1J2	2.18e-04	40	53	3	147
GeneFamily	Solute carriers	SLC7A8 SLC6A7 SLC52A1 SLC43A1 SLC22A10 SLC35E4	1.01e-03	395	53	6	752
GeneFamily	G protein-coupled receptors, Class A orphans	MAS1 MRGPRE MRGPRX4	1.55e-03	78	53	3	262
GeneFamily	Sterile alpha motif domain containing	SGMS1 SCMH1 EPHA5	2.19e-03	88	53	3	760
GeneFamily	Nucleoporins	AAAS NUP205	3.95e-03	32	53	2	1051
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	CXCR3 JAG1 CD164 FGFR1 ITGA1	5.83e-03	394	53	5	471
GeneFamily	Receptor Tyrosine Kinases\|CD molecules	FLT1 FGFR1	6.12e-03	40	53	2	321
GeneFamily	Blood group antigens\|CD molecules\|I-set domain containing\|Immunoglobulin like domain containing	FLT1 NEGR1 FGFR1	1.17e-02	161	53	3	593
Coexpression	MILI_PSEUDOPODIA_HAPTOTAXIS_DN	SGPP1 MYADM ERG28 SLC52A1 SGMS1 HGSNAT LHFPL6 CPD FGFR1 TMEM86A	2.45e-05	703	73	10	MM1055
Coexpression	GSE40274_FOXP3_VS_FOXP3_AND_XBP1_TRANSDUCED_ACTIVATED_CD4_TCELL_UP	FLT1 KNDC1 MFSD6L ITGA1 ESPL1	6.30e-05	150	73	5	M9146
Coexpression	MURARO_PANCREAS_ENDOTHELIAL_CELL	FLT1 P2RY6 JAG1 LHFPL6 ITGA1 EMP1 ADGRL4	6.74e-05	362	73	7	M39176
Coexpression	FAN_EMBRYONIC_CTX_BIG_GROUPS_BRAIN_ENDOTHELIAL	SLC7A8 FLT1 JAG1 LHFPL6 CPD ITGA1 ADGRL4	7.10e-05	365	73	7	M39018
Coexpression	WENG_POR_DOSAGE	CYP2C19 CYP2C9 CYP2C18	7.97e-05	30	73	3	MM1199
Coexpression	JONES_OVARY_ENDOTHELIAL	FLT1 JAG1 ITGA1 EMP1 ADGRL4	9.07e-05	162	73	5	M48350
Coexpression	FOSTER_KDM1A_TARGETS_UP	CYP2C18 CNTNAP2 DNAJC5G DCSTAMP CDH3 NLRP4	9.35e-05	263	73	6	M2512
Coexpression	LAKE_ADULT_KIDNEY_C28_INTERSTITIUM	NEGR1 SCMH1 LHFPL6 ITGA1	9.89e-05	86	73	4	M39247
Coexpression	MILI_PSEUDOPODIA_HAPTOTAXIS_DN	SGPP1 MYADM ERG28 SGMS1 HGSNAT LHFPL6 CPD FGFR1 TMEM86A	1.13e-04	681	73	9	M5314
Coexpression	WIEMANN_TELOMERE_SHORTENING_AND_CHRONIC_LIVER_DAMAGE_DN	CYP2C19 CYP2C9	1.14e-04	6	73	2	MM971
ToppCell	LPS-IL1RA-Endothelial-Endothelial-Artery\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TMTC1 FLT1 CYP2C18 JAG1 MMP16 TMEM64 ADGRL4	3.04e-08	190	74	7	aed65d584ca0c25f6a8313c66b421a6618af82ea
ToppCell	ICU-SEP-Myeloid-cDC2\|ICU-SEP / Disease, Lineage and Cell Type	P2RY6 NEGR1 JAG1 KNDC1 PIGW EMP1	4.73e-07	175	74	6	c44fd1cc827296de7300d4a60399bb945089a170
ToppCell	COVID-19-kidney-AQP1+SLC14A1+EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TMTC1 FLT1 JAG1 EMP1 CSGALNACT1 ADGRL4	5.40e-07	179	74	6	1ce8d18f63e8dd2d3db41fbeca4601bd3b305fba
ToppCell	COVID-19-Heart-EC_+_Pericyte\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TMTC1 FLT1 JAG1 LHFPL6 ITGA1 ADGRL4	5.95e-07	182	74	6	e67f3234165199085c793915ebb1f9bbd845e933
ToppCell	Control-Endothelial_cells-Endothelial_cells_(other)\|Control / group, cell type (main and fine annotations)	TMTC1 FLT1 SLC22A10 ITGA1 EMP1 ADGRL4	6.75e-07	186	74	6	c6075fe84226b370c5139066793844ad33ae2db1
ToppCell	Adult-Endothelial-endothelial_cell_of_artery\|Adult / Lineage, Cell type, age group and donor	TMTC1 FLT1 EMP1 MMP16 CSGALNACT1 ADGRL4	6.75e-07	186	74	6	2d1c4ea2e401db89971582ee54618a8b0c81b8ac
ToppCell	COVID-19-Heart-EC_2\|Heart / Disease (COVID-19 only), tissue and cell type	TMTC1 FLT1 TMEM87B JAG1 CSGALNACT1 ADGRL4	6.97e-07	187	74	6	40ffc06a3e3251d9b12da390210d3e045af7537a
ToppCell	LPS-IL1RA+antiTNF-Endothelial-Endothelial-Artery\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TMTC1 FLT1 JAG1 MMP16 CSGALNACT1 ADGRL4	7.42e-07	189	74	6	c45734970036e6d28d5e3fe7c9458fae38a3f624
ToppCell	human_hepatoblastoma-Endothelial_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	TMTC1 FLT1 EMP1 MMP16 CSGALNACT1 ADGRL4	7.65e-07	190	74	6	8d6ef93d69e96cd6921816d152bea3b0710cf147
ToppCell	COVID-19-Heart-EC_+_Pericyte\|Heart / Disease (COVID-19 only), tissue and cell type	TMTC1 FLT1 JAG1 LHFPL6 ITGA1 ADGRL4	7.65e-07	190	74	6	a21653bfb7bafbc273f94fa7c13bfb48cf8fd562
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_artery\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TMTC1 FLT1 EMP1 MMP16 CSGALNACT1 ADGRL4	7.65e-07	190	74	6	f6c38d197fd9d69a4f97cb2e72cd4747984c1a86
ToppCell	human_hepatoblastoma-Endothelial_cells\|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells)	TMTC1 FLT1 EMP1 MMP16 CSGALNACT1 ADGRL4	8.13e-07	192	74	6	e09f609fed033a25baacaf4a07bbbae1076da366
ToppCell	nucseq-Endothelial-Endothelial_Vascular-Endothelial_capillary\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TMTC1 FLT1 SLC22A10 LHFPL6 ITGA1 ADGRL4	8.38e-07	193	74	6	f582e939e3e08a8a3f71deec78c33715be8faa51
ToppCell	nucseq-Endothelial-Endothelial_Vascular-Endothelial_capillary-CAP1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TMTC1 FLT1 SLC22A10 LHFPL6 ITGA1 ADGRL4	8.38e-07	193	74	6	ad3f4fcc8e2816d696cbcde744dc16500e51ccac
ToppCell	COVID-19-kidney-PLVAP+EC\|kidney / Disease (COVID-19 only), tissue and cell type	TMTC1 FLT1 FGFR1 ITGA1 EMP1 ADGRL4	8.90e-07	195	74	6	a436483fec137584611f86b7a498a4dc2aa19cd3
ToppCell	COVID-19-kidney-Fibroblast-2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	RNF150 TMTC1 NEGR1 LHFPL6 ITGA1 OR1J2	8.90e-07	195	74	6	3d62ce1c696f47d4d7eb0c5bb0eec2c24b122bb2
ToppCell	nucseq-Endothelial\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TMTC1 FLT1 LHFPL6 ITGA1 EMP1 ADGRL4	9.44e-07	197	74	6	ebf9be068eaa658493fa7884fd19f34642922acb
ToppCell	cellseq-Endothelial\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TMTC1 FLT1 LHFPL6 ITGA1 EMP1 ADGRL4	1.00e-06	199	74	6	4757827efb393c429adec5079d18a173baf23d74
ToppCell	5'-Parenchyma_lung-Endothelial\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TMTC1 FLT1 LHFPL6 ITGA1 EMP1 ADGRL4	1.00e-06	199	74	6	c0a1ed48bebcd85cbbffb8ac50fb0f902b97f239
ToppCell	Sepsis-ICU-SEP-Myeloid-cDC2\|ICU-SEP / Disease, condition lineage and cell class	P2RY6 NEGR1 JAG1 KNDC1 PIGW EMP1	1.03e-06	200	74	6	09d5c3a3d2b42b15c769dc2bc14b6c0d5cc38f91
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Descending_Vasa_Recta_Endothelial_Cell_prolif\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 DNAJC5G CSGALNACT1 ADGRL4	8.44e-06	166	74	5	8e2faca6a2e76a625de04d6098aa6f98911945c6
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Afferent_/_Efferent_Arteriole_Endothelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 JAG1 SLC35E4 ADGRL4	9.21e-06	169	74	5	c7fc3a8c44f07c557b60d469717b66e2f5863d38
ToppCell	Adult-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D122\|Adult / Lineage, Cell type, age group and donor	TMTC1 FLT1 LHFPL6 ITGA1 ADGRL4	9.75e-06	171	74	5	bd20e85d36fa9d7ddc8afef6a1dea75efc9ee1dc
ToppCell	Adult-Endothelial-endothelial_cell_of_artery-D175\|Adult / Lineage, Cell type, age group and donor	TMTC1 EMP1 MMP16 CSGALNACT1 ADGRL4	1.09e-05	175	74	5	0a65ddfa8c2e8efb5b5338cf07661cb78157a23c
ToppCell	facs-Marrow-Granulocytes-3m-Myeloid-monocyte_+_promonocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYADM P2RY6 HGSNAT ITGA1 ARHGEF10L	1.09e-05	175	74	5	69b59ec58e64644deb7e07f31ef495ef4a6f6276
ToppCell	facs-Marrow-Granulocytes-3m-Myeloid-promonocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYADM P2RY6 HGSNAT ITGA1 ARHGEF10L	1.09e-05	175	74	5	4f7498b5a0ed52c348a5f94bcd41d830ba7954ea
ToppCell	droplet-Marrow-BM-1m-Lymphocytic-plasma_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC7A8 RNF150 P2RY6 TNFSF15 ARHGEF10L	1.15e-05	177	74	5	26bad614560609d318bfc9c235a698bca4e1c22c
ToppCell	390C-Endothelial_cells-Endothelial-E-\|390C / Donor, Lineage, Cell class and subclass (all cells)	TMTC1 FLT1 ITGA1 EMP1 ADGRL4	1.18e-05	178	74	5	804ac3725c1f88e2212172bfb9aa01d97a735621
ToppCell	390C-Endothelial_cells-Endothelial-E\|390C / Donor, Lineage, Cell class and subclass (all cells)	TMTC1 FLT1 ITGA1 EMP1 ADGRL4	1.18e-05	178	74	5	ad6dc4a375664c919bd48c35c48a561fc5a7de8c
ToppCell	COVID-19-Heart-EC_2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TMTC1 FLT1 JAG1 CSGALNACT1 ADGRL4	1.22e-05	179	74	5	2a53d94f6c30bf887dfe88f1693ea057218c852d
ToppCell	PCW_05-06-Endothelial-Endothelial_immature-endo_immature3_(11)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	FLT1 SLC22A10 DNAJC5G EMP1 ADGRL4	1.25e-05	180	74	5	7d4cb0ab9f96088cbc5db3096d884a1e5ce4cb5d
ToppCell	ICU-NoSEP-Myeloid-tDC\|ICU-NoSEP / Disease, Lineage and Cell Type	CXCR3 FLT1 P2RY6 LHFPL6 EMP1	1.25e-05	180	74	5	be665e801512f6aaf6b3ecb26153bbdeb24619ac
ToppCell	5'-GW_trimst-2-SmallIntestine-Endothelial-blood_vessel_EC-Mature_arterial_EC\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FLT1 JAG1 EMP1 MMP16 ADGRL4	1.28e-05	181	74	5	0ba91575fe8851788cebc4cf5a6d76680bf586c5
ToppCell	COVID-19-Heart-EC_3\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TMTC1 FLT1 LHFPL6 MMP16 ADGRL4	1.35e-05	183	74	5	ff95382cfed592190d0636d2b750328471f82e0d
ToppCell	3'-Child09-12-SmallIntestine-Endothelial-blood_vessel_EC-Mature_arterial_EC\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TMTC1 FLT1 JAG1 CSGALNACT1 ADGRL4	1.39e-05	184	74	5	842473fa415575441b595073a994b6d621169776
ToppCell	LA-07._Pericyte\|LA / Chamber and Cluster_Paper	TMTC1 FLT1 JAG1 LHFPL6 ITGA1	1.43e-05	185	74	5	ba5baa4d7f097108622674de5b7f4fd279843d24
ToppCell	Adult-Endothelial-capillary_endothelial_cell_(Cap1)-D231\|Adult / Lineage, Cell type, age group and donor	TMTC1 FLT1 SLC22A10 ITGA1 ADGRL4	1.43e-05	185	74	5	07f9f38f0739d7c830641723a38385550ac1ac92
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_artery-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TMTC1 FLT1 EMP1 MMP16 ADGRL4	1.43e-05	185	74	5	a7ae76058b2082020cadec49d63b9f4e24d21734
ToppCell	Control-Endothelial-Endothelial-Artery\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TMTC1 FLT1 JAG1 MMP16 ADGRL4	1.46e-05	186	74	5	2d3a975d2bf92e18e3410dd413fc9f84831d82de
ToppCell	droplet-Lung-nan-3m-Endothelial-Vein_endothelial_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLT1 JAG1 EMP1 MMP16 ADGRL4	1.50e-05	187	74	5	64dd28b23eda7dfb7fd069be2742de7bad0fd87a
ToppCell	Control-Endothelial_cells-Endothelial_cells_(general)\|Control / group, cell type (main and fine annotations)	TMTC1 FLT1 SLC22A10 LHFPL6 ADGRL4	1.50e-05	187	74	5	fb5bcbc8effdbf0e57fcb71aca990a4aa0d65ce8
ToppCell	droplet-Lung-nan-3m-Endothelial-vein_endothelial_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLT1 JAG1 EMP1 MMP16 ADGRL4	1.50e-05	187	74	5	b535d5447bf15e95dcf025a0a455628b956fc857
ToppCell	Control-Endothelial_cells-Arterial_endothelial_cells\|Control / group, cell type (main and fine annotations)	TMTC1 FLT1 EMP1 CSGALNACT1 ADGRL4	1.50e-05	187	74	5	81affaab3fe3e1daea45ada6445e906ddd33950e
ToppCell	PCW_05-06-Endothelial-Endothelial_immature-endo_immature4_(5)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	FLT1 SLC22A10 EMP1 CSGALNACT1 ADGRL4	1.54e-05	188	74	5	b9c5d573fc5ab0f7f38c55d006f9576634b05462
ToppCell	Control-Endothelial_cells\|Control / group, cell type (main and fine annotations)	TMTC1 FLT1 SLC22A10 LHFPL6 ADGRL4	1.54e-05	188	74	5	3953b08abfea93468fc8d177bdb16ca7c6ffa1ab
ToppCell	3'-Adult-Distal_Rectal-Endothelial\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TMTC1 FLT1 FGFR1 EMP1 ADGRL4	1.58e-05	189	74	5	0c612ff5f882f2d8ec744a347780bbbe7cc471bd
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Descending_Vasa_Recta_Endothelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 LHFPL6 CSGALNACT1 ADGRL4	1.58e-05	189	74	5	6463890d8dbee4bc198f91628a5f784970de786a
ToppCell	LPS_only-Endothelial-Endothelial-Artery\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TMTC1 FLT1 MMP16 CSGALNACT1 ADGRL4	1.58e-05	189	74	5	b028466fcd36fdeceec752e55a24286a1cd62ae4
ToppCell	3'-Adult-Distal_Rectal-Endothelial-blood_vessel_EC\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TMTC1 FLT1 FGFR1 EMP1 ADGRL4	1.58e-05	189	74	5	bc8949bd4f425ed36e2c05e653c94cb1593c5bee
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Afferent_/_Efferent_Arteriole_Endothelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 JAG1 EMP1 ADGRL4	1.62e-05	190	74	5	bf9bc57a605c7e3979bc4f7260e6fb92c3eb8690
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	RNF150 SGMS1 CPD EMP1 CDH3	1.62e-05	190	74	5	bf4511395fa97efd1c1cd17cc9bebb0271ee7f0e
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	RNF150 SGMS1 CPD EMP1 CDH3	1.62e-05	190	74	5	b6b8964b4910083499681b5fdf554e127b6a4c4e
ToppCell	COVID-19-kidney-AQP1+SLC14A1+EC\|kidney / Disease (COVID-19 only), tissue and cell type	TMTC1 FLT1 JAG1 EMP1 ADGRL4	1.62e-05	190	74	5	1519f34d31fe0817184c5865a0bc9f0cb479b1a4
ToppCell	3'-Distal_airway-Endothelial-Blood_vessel_EC-vein_endothelial_cell-EC_venous_systemic-EC_venous_systemic_L.2.2.0.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	FLT1 JAG1 PIGW EMP1 ADGRL4	1.62e-05	190	74	5	a318d80dd5cc33d43048883b0e7844b5aa280aab
ToppCell	droplet-Marrow-nan-24m-Myeloid-promonocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYADM HGSNAT SLC35E4 ITGA1 ARHGEF10L	1.62e-05	190	74	5	e2fdbfaf08da3274b6bdda615386aa880040a90a
ToppCell	3'-Child04-06-SmallIntestine-Endothelial-blood_vessel_EC-Mature_arterial_EC\|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TMTC1 FLT1 JAG1 EMP1 ADGRL4	1.62e-05	190	74	5	ec6b8e2852e1cce0217ff61243defe98b2351640
ToppCell	nucseq-Endothelial-Endothelial_Vascular-Endothelial_large_blood_vessel-AEC\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TMTC1 FLT1 EMP1 CSGALNACT1 ADGRL4	1.66e-05	191	74	5	50601ef0a5a8f2c2120922989e08e85bf2d9b4ab
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	RNF150 SGMS1 CPD EMP1 CDH3	1.66e-05	191	74	5	2fa1b9e76a0ed2d2f0de74349e266cf4a5f51aad
ToppCell	LPS-antiTNF-Endothelial-Endothelial-Artery\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TMTC1 FLT1 JAG1 MMP16 ADGRL4	1.66e-05	191	74	5	4b3d5157344dbfbf4fab518611cd9fa37fac7bd9
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Descending_Vasa_Recta_Endothelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 JAG1 EMP1 ADGRL4	1.70e-05	192	74	5	bacbaef1f230051335f4433e55db07a161b96b4c
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Afferent_/_Efferent_Arteriole_Endothelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 EMP1 CSGALNACT1 ADGRL4	1.70e-05	192	74	5	3259cb89d6bcf0a3c6ff1f64d85e8a1f54124e91
ToppCell	Endothelial-Endothelial-B\|Endothelial / shred on cell class and cell subclass (v4)	MYADM FLT1 LHFPL6 FGFR1 EMP1	1.70e-05	192	74	5	f8d7bd81e031d09a557722627c2f6180811cc6ab
ToppCell	facs-Aorta-Heart-3m-Mesenchymal\|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CD164 LHFPL6 FGFR1 CDH3 ARHGEF10L	1.70e-05	192	74	5	0dc1f46e40346ed0b286e53b106a812441575100
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 LHFPL6 CSGALNACT1 ADGRL4	1.70e-05	192	74	5	28eb3a5728e8901bcb5ba12f6b009f41b065fa37
ToppCell	PCW_05-06-Endothelial-Endothelial_immature-endo_immature1_(0)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	FLT1 SLC22A10 EMP1 CSGALNACT1 ADGRL4	1.75e-05	193	74	5	2661ad9107ed9231e4afea4442a79051139a31df
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Descending_Vasa_Recta_Endothelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 JAG1 LHFPL6 ADGRL4	1.75e-05	193	74	5	2e72309607902dabe3218888b22a77fe941f3570
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Descending_Vasa_Recta_Endothelial_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 JAG1 LHFPL6 ADGRL4	1.75e-05	193	74	5	cc355b2ed6510619cad969ae074126d7c8db784d
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Afferent_/_Efferent_Arteriole_Endothelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 JAG1 EMP1 ADGRL4	1.75e-05	193	74	5	0b328f725f6feba263783eaca60c142e80df90f3
ToppCell	COVID-19-kidney-FLT1+PLVAP+EC\|kidney / Disease (COVID-19 only), tissue and cell type	FLT1 FGFR1 ITGA1 EMP1 ADGRL4	1.75e-05	193	74	5	479abb1cd2eb978b8a4fdb900069a6329fc8cade
ToppCell	5'-Parenchyma_lung-Endothelial-Blood_vessel_EC-capillary_endothelial_cell-EC_aerocyte_capillary-EC_aerocyte_capillary_L.2.0.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	FLT1 LHFPL6 ITGA1 EMP1 ADGRL4	1.75e-05	193	74	5	aaf681f16f310168e4719464814a1fc0a2f8431a
ToppCell	facs-Lung-nan-3m-Endothelial-endothelial_cell_of_lung\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLT1 SGMS1 ITGA1 EMP1 ADGRL4	1.79e-05	194	74	5	f159ef8541d75a4e98468947f231bb463bec922c
ToppCell	COPD-Endothelial-VE_Capillary_B\|COPD / Disease state, Lineage and Cell class	FLT1 LHFPL6 ITGA1 EMP1 ADGRL4	1.79e-05	194	74	5	18b7f901c12ca4f21f9a1eafd092aefe4d668b6d
ToppCell	facs-Diaphragm-Limb_Muscle-3m-Mesenchymal\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYADM CLDN25 LHFPL6 FGFR1 EMP1	1.84e-05	195	74	5	4d63e0dca30ae57960459d2fbcba09122273e37b
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Descending_Vasa_Recta_Endothelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 LHFPL6 CSGALNACT1 ADGRL4	1.84e-05	195	74	5	6bdef651cf73d7381e5012d0eb3c809138fb6b92
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NEGR1 LHFPL6 FGFR1 EMP1 MMP16	1.84e-05	195	74	5	ff0aa455e9844a6d7ae57ff59fb6cea825cf1fc2
ToppCell	facs-Diaphragm-Limb_Muscle-3m-Mesenchymal-nan\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYADM CLDN25 LHFPL6 FGFR1 EMP1	1.84e-05	195	74	5	661af601a3561fe3aacf2444ad7b8927fa88b48a
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Descending_Vasa_Recta_Endothelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 EMP1 CSGALNACT1 ADGRL4	1.84e-05	195	74	5	d35102f95bb1e419d2df05ff0a01b6c5c923acef
ToppCell	ASK440-Endothelial\|ASK440 / Donor, Lineage and Cell class of Lung cells from Dropseq	TMTC1 FLT1 LHFPL6 EMP1 ADGRL4	1.84e-05	195	74	5	1cdaab17866a1e5170e0f6bfcc69134425fdd8df
ToppCell	3'-Pediatric_IBD-SmallIntestine-Endothelial-blood_vessel_EC-Mature_arterial_EC\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TMTC1 FLT1 JAG1 EMP1 ADGRL4	1.84e-05	195	74	5	b0979c1b5e4576468b8fe4e9027650859e598b34
ToppCell	Children_(3_yrs)-Endothelial\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TMTC1 FLT1 LHFPL6 ITGA1 ADGRL4	1.84e-05	195	74	5	094cf6591daa5ffad36e44122b6f524a3a34c2fd
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 JAG1 EMP1 ADGRL4	1.84e-05	195	74	5	77e47d2e8b3eb7f7c9620369ccaf87581f923bdb
ToppCell	facs-Limb_Muscle-ForelimbandHindlimb-3m-Mesenchymal-nan\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYADM CD164 CLDN25 LHFPL6 FGFR1	1.88e-05	196	74	5	66d76249bd2770cdddff2c1fe59a016e95da2124
ToppCell	5'-Parenchyma_lung-Endothelial-Blood_vessel_EC-vein_endothelial_cell-EC_venous_systemic-EC_venous_systemic_L.2.2.0.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TMTC1 FLT1 EMP1 MMP16 ADGRL4	1.88e-05	196	74	5	5609b2d93172a488b35d854298a3a4e504e17e28
ToppCell	5'-Parenchyma_lung-Endothelial-Blood_vessel_EC-pulmonary_artery_endothelial_cell-EC_arterial-EC_arterial_L.2.4.1.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TMTC1 FLT1 EMP1 CSGALNACT1 ADGRL4	1.88e-05	196	74	5	cf7f384c1771274e766bab03ecc3dfbd13f2df60
ToppCell	nucseq-Endothelial-Endothelial_Vascular\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TMTC1 FLT1 LHFPL6 ITGA1 ADGRL4	1.88e-05	196	74	5	686533fd3fba8e4df96b9dd1307e870e89db4332
ToppCell	facs-Limb_Muscle-ForelimbandHindlimb-3m-Mesenchymal\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYADM CD164 CLDN25 LHFPL6 FGFR1	1.88e-05	196	74	5	9bd4c146fc7555e32adfa393b3a07846eb826d25
ToppCell	5'-Adult-LargeIntestine-Endothelial-blood_vessel_EC-Mature_arterial_EC\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TMTC1 FLT1 JAG1 EMP1 ADGRL4	1.93e-05	197	74	5	61b1b10a017cbeb17f8529fcae66cba77ee2f115
ToppCell	Tracheal-NucSeq-Epithelial-Epi_submucosal-gland-Myoepithelial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	RNF150 TMTC1 FGFR1 ITGA1 CDH3	1.93e-05	197	74	5	f0475ad9c09c6da418dba17d3d3c1aaa2ef9ab4e
ToppCell	facs-Trachea-3m\|Trachea / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	AMFR MYADM CD164 LHFPL6 FGFR1	1.93e-05	197	74	5	e77016d64b1cac9825fec7cfe5071f1567401187
ToppCell	Parenchyma_Control_(B.)-Endothelial-TX-Endothelial-1\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	TMTC1 FLT1 EMP1 MMP16 ADGRL4	1.93e-05	197	74	5	f969685dee212f33a6f09e54c0cd1fd24ffef546
ToppCell	Bronchial-NucSeq-Endothelial-Endothelia_vascular-VE_capillary\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	TMTC1 FLT1 SLC22A10 ITGA1 ADGRL4	1.93e-05	197	74	5	81718164c9802ee20c860ffbda7e62d5e9a76f16
ToppCell	facs-Trachea-nan-3m\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	AMFR MYADM CD164 LHFPL6 FGFR1	1.93e-05	197	74	5	0353d925ee4b7aefc2c51b5fab873f465cdf9ebc
ToppCell	Lung_Parenchyma-Control-Endothelial-Endothelial-Endothelial-1\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	TMTC1 FLT1 EMP1 MMP16 ADGRL4	1.93e-05	197	74	5	1a137af40697137bb9d2b5caf2b1ffda55f04461
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 NEGR1 LHFPL6 FGFR1 ITGA1	1.93e-05	197	74	5	9b480f9c799a244bfee64487abd8a1bf07c9a3a2
ToppCell	facs-Diaphragm-Limb_Muscle-3m\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYADM CD164 CLDN25 FGFR1 EMP1	1.93e-05	197	74	5	b0e2ea81308bce289cb7cbea0e27de1d01afeed2
ToppCell	Lung_Parenchyma-Control-Endothelial-Endothelial-Endothelial-1-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	TMTC1 FLT1 EMP1 MMP16 ADGRL4	1.93e-05	197	74	5	96d63a8d00583e2aa0a38412e2ae27e23f399493
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 FLT1 LHFPL6 CSGALNACT1 ADGRL4	1.98e-05	198	74	5	b027a141ab531d0f5d6a26811a53427e7b0771dd
ToppCell	3'-Pediatric_IBD-SmallIntestine-Endothelial-blood_vessel_EC\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TMTC1 FLT1 P2RY6 EMP1 ADGRL4	1.98e-05	198	74	5	5b86dc00acf8ac2ede008f5d79c09996485bf250
ToppCell	5'-Adult-Distal_Rectal-Endothelial-blood_vessel_EC-Mature_arterial_EC\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TMTC1 FLT1 JAG1 EMP1 ADGRL4	1.98e-05	198	74	5	8a55589b9244283e4b0b423a4a6d6202e8e0fec9
ToppCell	5'-Adult-Distal_Rectal-Endothelial-blood_vessel_EC\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TMTC1 FLT1 JAG1 EMP1 ADGRL4	1.98e-05	198	74	5	d1f54ed3ef5e05ebda7da999e172d168dc6802cd
Computational	Cytochrome P450.	CYP2C19 CYP2C9 CYP2C18	1.22e-05	14	36	3	MODULE_106
Computational	Genes in the cancer module 12.	SLC6A7 FLT1 CYP2C9 CYP2C18 JAG1 ESPL1 LY6G6C PINK1	2.55e-04	519	36	8	MODULE_13
Drug	4',5-dihydroxydiclofenac	CYP2C19 CYP2C9 CYP2C18	6.55e-07	6	74	3	CID003052567
Drug	3'-hydroxydiclofenac	CYP2C19 CYP2C9 CYP2C18	6.55e-07	6	74	3	CID000112230
Drug	4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide	CYP2C19 CYP2C9 CYP2C18	2.73e-06	9	74	3	ctd:C545880
Drug	Acenocoumarol	CYP2C19 CYP2C9 CYP2C18	2.73e-06	9	74	3	ctd:D000074
Drug	5-hydroxydiclofenac	CYP2C19 CYP2C9 CYP2C18	7.10e-06	12	74	3	CID003052566
Drug	carveol	CYP2C19 CYP2C9 MAS1	7.10e-06	12	74	3	CID000007438
Drug	nitinol	AAAS NEGR1 MAS1	9.21e-06	13	74	3	CID003081502
Drug	dibenzylfluorescein	CYP2C19 CYP2C9	1.04e-05	2	74	2	ctd:C558664
Drug	DB04229	SGMS1 JAG1	1.04e-05	2	74	2	CID005289611
Drug	2'-(glutathion-S-yl)-deschlorodiclofenac	CYP2C19 CYP2C9 CYP2C18	1.46e-05	15	74	3	ctd:C586542
Drug	N-desethyloxybutynin	CYP2C19 CYP2C9 MAS1	1.46e-05	15	74	3	CID000133577
Drug	1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane	CYP2C19 CYP2C9 CYP2C18	1.79e-05	16	74	3	ctd:C495657
Drug	ginsenoside Rf	SLC6A7 CYP2C19 CYP2C9	2.17e-05	17	74	3	CID000441922
Drug	Azamulinum	CYP2C19 CYP2C9 CYP2C18	2.60e-05	18	74	3	CID003086060
Drug	D 703	CYP2C19 CYP2C9 CYP2C18	2.60e-05	18	74	3	CID000054088
Drug	hydroxytolbutamide	CYP2C19 CYP2C9 CYP2C18	3.08e-05	19	74	3	CID000003656
Drug	picoxystrobin	CYP2C19 CYP2C9	3.12e-05	3	74	2	ctd:C556557
Drug	2-hydroxychlorpropamide	CYP2C19 CYP2C9	3.12e-05	3	74	2	CID003082454
Drug	mono-N-demethyladinazolam	CYP2C19 CYP2C9	3.12e-05	3	74	2	ctd:C050132
Drug	Delavirdine	CYP2C19 CYP2C9	3.12e-05	3	74	2	ctd:D020008
Drug	acetanilide	TMUB1 CYP2C19 CYP2C9 JAG1	3.32e-05	56	74	4	CID000000904
Drug	3C etc	CYP2C19 CYP2C9 CYP2C18	3.61e-05	20	74	3	CID000164045
Drug	Risperidone [106266-06-2]; Up 200; 9.8uM; MCF7; HT_HG-U133A	CNTNAP2 HGSNAT FGFR1 EMP1 MMP16 CFAP69	4.17e-05	195	74	6	7449_UP
Drug	Moricizine hydrochloride [31883-05-3]; Down 200; 8.6uM; HL60; HT_HG-U133A	AMFR CXCR3 LHFPL6 FGFR1 EMP1 ARHGEF10L	4.54e-05	198	74	6	2959_DN
Drug	Tranylcypromine hydrochloride [1986-47-6]; Up 200; 23.6uM; MCF7; HT_HG-U133A	SLC7A8 DUOX1 MAS1 SLC43A1 JAG1 FGFR1	4.54e-05	198	74	6	5996_UP
Drug	BP-4,5-oxide	SLC6A7 CYP2C19 CYP2C9 CYP2C18	4.66e-05	61	74	4	CID000037786
Drug	Folic acid [59-30-3]; Up 200; 9uM; PC3; HT_HG-U133A	AMFR AAAS P2RY6 SLC43A1 FGFR1 MMP16	4.67e-05	199	74	6	5844_UP
Drug	3'-amino-3'-deoxythymidine	FLT1 CYP2C19 CYP2C9	5.57e-05	23	74	3	CID000108074
Drug	1-(6-((2-(dimethylamino)ethyl)(methyl)amino)-1,3-dimethyl-1H-pyrazolo(3,4-b)pyridine-5-carbonyl)-3-(3-isopropoxyphenyl)urea	CYP2C19 CYP2C9	6.23e-05	4	74	2	ctd:C558737
Drug	7,8-dihydromethysticin	CYP2C19 CYP2C9	6.23e-05	4	74	2	ctd:C107882
Drug	methysticin	CYP2C19 CYP2C9	6.23e-05	4	74	2	ctd:C076881
Drug	rabeprazole-thioether	CYP2C19 CYP2C9	6.23e-05	4	74	2	ctd:C523099
Drug	Tolbutamide	CYP2C19 CYP2C9 CYP2C18	7.20e-05	25	74	3	ctd:D014044
Drug	1,4-naphthoquinone	CYP2C19 CYP2C9 CYP2C18	8.12e-05	26	74	3	ctd:C035342
Drug	BBCH	SLC7A8 SLC6A7 SLC43A1	9.11e-05	27	74	3	CID000115288
Drug	bufuralol	CYP2C19 CYP2C9	1.04e-04	5	74	2	ctd:C010831
Drug	2-oxo-clopidogrel	CYP2C19 CYP2C9	1.04e-04	5	74	2	ctd:C540904
Drug	benfuracarb	CYP2C19 CYP2C9	1.04e-04	5	74	2	ctd:C096128
Drug	mono(2-ethyl-5-hydroxyhexyl) phthalate	CYP2C19 CYP2C9	1.04e-04	5	74	2	ctd:C479069
Drug	(hydrochloride)	CYP2C19 CYP2C9 CYP2C18	1.13e-04	29	74	3	CID000004923
Drug	clobazam	CACNA1B CYP2C19 CYP2C18	1.13e-04	29	74	3	CID000002789
Drug	tofisopam	CYP2C19 CYP2C9 CYP2C18	1.13e-04	29	74	3	CID000005502
Drug	triphenylstannanylium	CYP2C19 CYP2C9 CYP2C18	1.13e-04	29	74	3	CID000091481
Drug	BP-7,8-oxide	CYP2C19 CYP2C9 CYP2C18	1.53e-04	32	74	3	CID000037455
Drug	4,4'-cyclohexylidenebisphenol	CYP2C19 CYP2C9	1.55e-04	6	74	2	ctd:C570106
Drug	mono-OH	CYP2C9 CYP2C18	1.55e-04	6	74	2	CID000183679
Drug	avasimibe	CYP2C19 CYP2C9	1.55e-04	6	74	2	ctd:C423185
Drug	mono(2-ethyl-5-oxohexyl)phthalate	CYP2C19 CYP2C9	1.55e-04	6	74	2	ctd:C080276
Drug	4'-hydroxyflurbiprofen	CYP2C19 CYP2C9	1.55e-04	6	74	2	CID000157678
Drug	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate	FLT1 FGFR1	1.55e-04	6	74	2	ctd:C560274
Drug	AC1O5Z5L	CYP2C19 CYP2C9	1.55e-04	6	74	2	CID006443527
Drug	mepirodipine	CYP2C19 CYP2C9	1.55e-04	6	74	2	ctd:C050699
Drug	Cyclodextrins	CYP2C19 CYP2C9	1.55e-04	6	74	2	ctd:D003505
Drug	1-naphthol	CYP2C19 CYP2C9 JAG1	1.68e-04	33	74	3	ctd:C029350
Drug	sulprofos	CYP2C19 CYP2C9	2.17e-04	7	74	2	CID000037125
Drug	5-n-butyl-pyrazolo(1,5-a)pyrimidine	CYP2C19 CYP2C9	2.17e-04	7	74	2	ctd:C547858
Drug	5-fluorotryptamine	CYP2C19 CYP2C9	2.17e-04	7	74	2	ctd:C034536
Drug	5-hydroxydiclofenac	CYP2C19 CYP2C18	2.17e-04	7	74	2	ctd:C117715
Drug	desmethyltrimipramine	CYP2C19 CYP2C9	2.17e-04	7	74	2	CID000160632
Drug	quinidine-N-oxide	CYP2C19 CYP2C9	2.17e-04	7	74	2	CID000050979
Drug	12-hydroxyellipticine	CYP2C19 CYP2C9	2.17e-04	7	74	2	ctd:C517214
Drug	6-Fluoro-6-desoxyoxymorphone	CYP2C19 CYP2C9	2.17e-04	7	74	2	CID005486899
Drug	16-O-demethylaconitine	CYP2C19 CYP2C9	2.17e-04	7	74	2	ctd:C486136
Drug	Voriconazole	CYP2C19 CYP2C9	2.17e-04	7	74	2	ctd:D065819
Drug	felodipine	CACNA1B CYP2C19 CYP2C9 CYP2C18 ADGRL4	2.26e-04	169	74	5	CID000003333
Drug	Bilirubin	SGPP1 FLT1 CYP2C9 CPD CLCC1	2.73e-04	176	74	5	ctd:D001663
Drug	13-hydroxyeicosatetraenoic acid	CYP2C19 CYP2C9	2.88e-04	8	74	2	CID006439499
Drug	5-fluoro-alpha-methyltryptamine	CYP2C19 CYP2C9	2.88e-04	8	74	2	ctd:C051101
Drug	5-methyltryptamine	CYP2C19 CYP2C9	2.88e-04	8	74	2	ctd:C027552
Drug	AC1L4AGK	CYP2C19 CYP2C9	2.88e-04	8	74	2	CID000182186
Drug	11-HODE	CYP2C19 CYP2C9	2.88e-04	8	74	2	CID006438497
Drug	5-bromotryptamine	CYP2C19 CYP2C9	2.88e-04	8	74	2	ctd:C040997
Drug	4-hydroxyalprazolam	CYP2C19 CYP2C9	2.88e-04	8	74	2	CID000182017
Drug	sulforidazine	CYP2C19 CYP2C9	2.88e-04	8	74	2	CID000031765
Drug	clobazam	CYP2C19 CYP2C18	2.88e-04	8	74	2	ctd:C012255
Drug	desmethylmaprotiline	CYP2C19 CYP2C9	2.88e-04	8	74	2	CID000119409
Drug	germacrone	CYP2C19 CYP2C9	2.88e-04	8	74	2	ctd:C048393
Drug	11 beta-hydroxytestosterone	CYP2C19 CYP2C9	2.88e-04	8	74	2	CID000114920
Drug	7-methyltryptamine	CYP2C19 CYP2C9	2.88e-04	8	74	2	ctd:C036696
Drug	1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid	CYP2C19 CYP2C9	2.88e-04	8	74	2	ctd:C585955
Drug	PCB 77	CYP2C19 CYP2C9 CYP2C18 JAG1	2.95e-04	98	74	4	CID000036187
Drug	furafylline	CYP2C19 CYP2C9 CYP2C18	3.21e-04	41	74	3	CID000003433
Drug	L 654969	CYP2C19 CYP2C9 EMP1	3.45e-04	42	74	3	CID000005218
Drug	desipramine	CYP2C19 CYP2C9 CPD TNFSF15 ADGRL4	3.70e-04	188	74	5	CID000002995
Drug	aminohexane	JAG1 EMP1	3.70e-04	9	74	2	CID000201427
Drug	cis-linoleic acid	CYP2C19 CYP2C9	3.70e-04	9	74	2	CID006431005
Drug	Fluorescein	CYP2C19 CYP2C9	3.70e-04	9	74	2	ctd:D019793
Drug	AC1L8U1Y	CYP2C19 CYP2C9	3.70e-04	9	74	2	CID000408120
Drug	5-chlorotryptamine	CYP2C19 CYP2C9	3.70e-04	9	74	2	ctd:C529169
Drug	3-(2-(4-(3-chloro-2-methylphenyl)1-piperazinyl)ethyl)5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazol dihydrochloride 3.5 hydrate	CYP2C19 CYP2C9	3.70e-04	9	74	2	ctd:C109602
Drug	2-nitroanisole	CYP2C19 CYP2C9	3.70e-04	9	74	2	ctd:C005328
Drug	5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methylbenzoic acid	CYP2C19 CYP2C9	3.70e-04	9	74	2	ctd:C000588958
Drug	Tryptamines	CYP2C19 CYP2C9	3.70e-04	9	74	2	ctd:D014363
Drug	N-desmethylclobazam	CYP2C19 CYP2C18	3.70e-04	9	74	2	CID000089657
Drug	phenylcyclopropane	CYP2C19 CYP2C9	3.70e-04	9	74	2	CID000070112
Drug	Sesquimustard	AMFR CPD MMP16	3.70e-04	43	74	3	CID000019092
Drug	cryptotanshinone	CYP2C19 CYP2C9 JAG1	3.70e-04	43	74	3	CID000160254
Drug	sulfaphenazole	CYP2C19 CYP2C9 CYP2C18	3.97e-04	44	74	3	CID000005335
Drug	polybrominated biphenyl	CYP2C19 CYP2C9 CYP2C18	3.97e-04	44	74	3	CID000042948
Drug	Cyclizine hydrochloride [303-25-3]; Up 200; 13.2uM; MCF7; HT_HG-U133A	DUOX1 CYP2C9 SLC52A1 CNTNAP2 FGFR1	4.27e-04	194	74	5	5525_UP
Disease	X-21258 measurement	CYP2C19 CYP2C9 CYP2C18	1.28e-08	3	70	3	EFO_0800802
Disease	X-14473 measurement	CYP2C19 CYP2C18	5.55e-06	2	70	2	EFO_0021370
Disease	cyclo(leu-pro) measurement	CYP2C19 CYP2C18	1.66e-05	3	70	2	EFO_0800676
Disease	Major Depressive Disorder	CYP2C19 CYP2C9 CNTNAP2 FGFR1 EMP1 PINK1	2.48e-05	243	70	6	C1269683
Disease	Unipolar Depression	CYP2C19 CYP2C9 CNTNAP2 FGFR1 EMP1 PINK1	3.54e-05	259	70	6	C0041696
Disease	S-6-hydroxywarfarin to S-warfarin ratio measurement	RNF150 CYP2C19 CYP2C9 CYP2C18	5.83e-05	88	70	4	EFO_0803332
Disease	glycine conjugate of C10H14O2 (1) measurement	CYP2C9 CYP2C18	1.16e-04	7	70	2	EFO_0800655
Disease	Osteitis Deformans	DCSTAMP NUP205	1.98e-04	9	70	2	C0029401
Disease	plasma clozapine-to-N-desmethylclozapine ratio measurement	CYP2C19 CYP2C18	1.98e-04	9	70	2	EFO_0600040
Disease	X-11308 measurement	CYP2C19 CYP2C9	3.01e-04	11	70	2	EFO_0800693
Disease	ecosanoids measurement	CYP2C9 CYP2C18 SLC22A10	3.07e-04	55	70	3	EFO_0020044
Disease	thymol sulfate measurement	CYP2C19 CYP2C9	3.61e-04	12	70	2	EFO_0021170
Disease	osteitis deformans	DCSTAMP NUP205	4.25e-04	13	70	2	EFO_0004261
Disease	vascular dementia (biomarker_via_orthology)	FLT1 FGFR1	4.96e-04	14	70	2	DOID:8725 (biomarker_via_orthology)
Disease	gliosarcoma	CYP2C18 FGFR1	6.52e-04	16	70	2	C0206726
Disease	metabolonic lactone sulfate measurement	CYP2C9 CYP2C18	9.24e-04	19	70	2	EFO_0800659
Disease	Giant Cell Glioblastoma	JAG1 SLC22A10 FGFR1	1.06e-03	84	70	3	C0334588
Disease	platelet reactivity measurement, response to clopidogrel	CYP2C19 CYP2C18	1.36e-03	23	70	2	EFO_0004985, GO_1903493
Disease	S-warfarin to R-warfarin ratio measurement	CYP2C19 CYP2C9 CYP2C18	1.51e-03	95	70	3	EFO_0803331
Disease	peptide measurement	CACNA1B FLT1 MMP16	2.24e-03	109	70	3	EFO_0010520
Disease	Glioblastoma Multiforme	JAG1 SLC22A10 PINK1	2.36e-03	111	70	3	C1621958
Disease	coronary artery disease, factor VII measurement	FLT1 MAS1 LY6G6C	2.36e-03	111	70	3	EFO_0001645, EFO_0004619

Protein segments in the cluster

Peptide	Gene	Start	Entry
SSARWALTCCLVLLP	TNFSF15	31	O95150
IISLICLAICIFTFW	ADGRL4	436	Q9HBW9
ARVTLTCLAVWGLCL	CXCR3	166	P49682
KIWGTLLALLCILCT	EDDM3B	6	P56851
ASVLAVACQSCILIW	AAAS	206	Q9NRG9
LCVTSLLICQGLLWV	ARHGEF10L	1066	Q9HCE6
WISRVVVLLVLLCCA	CSGALNACT1	11	Q8TDX6
WTCLLLCAALRTLLA	EPHA5	41	P54756
LSLLGWVCSCVTTIL	CLDN25	16	C9JDP6
WVVLCVVALNTLCVA	CACNA1B	486	Q00975
SLCSFIIETCLFILW	NUP205	1891	Q92621
AICLLLLTWVNCSSV	SLC7A8	166	Q9UHI5
TLCCFPLVSLLSAWI	DUOX1	601	Q9NRD9
FLSGATTLVCWLCIL	EMP1	96	P54849
QRCACLLALSWVVSI	OR1B1	141	Q8NGR6
CVFLVAVSWILSCAS	OR1J2	141	Q8NGS2
LVCALLWALSCLVTT	MAS1	151	P04201
WLAAVLLSLCCLLPS	NEGR1	16	Q7Z3B1
RSLLWAATCLGVLCV	CD164	6	Q04900
TWSGLACLIFLNCTL	SLC43A1	201	O75387
ACCVALLLWLALLLS	MFSD6L	526	Q8IWD5
TLCQAALLLCSWRAA	PINK1	566	Q9BXM7
AAASWIITCVLLCCS	DCSTAMP	61	Q9H295
WTLLSSVIRCLCAID	ERG28	56	Q9UKR5
TCTLCAFISLVWLRE	MARCHF6	151	O60337
TWCFCFSVTLIILIV	MYADM	71	Q96S97
SICQIPLLCWILCTS	NLRP4	336	Q96MN2
CWLLTVVLRCCVSFN	ITGA1	16	P56199
TLWLVAAVLLALLCC	MRGPRE	176	Q86SM8
WTLCIQVLTSSCALD	FAAP100	541	Q0VG06
IWALLSFLCAATSCV	LHFPL6	11	Q9Y693
LLTLSVLLCWVSADI	LY6G6C	6	O95867
CNLLVTVSWILSCTN	OR1J4	141	Q8NGS1
SCWFKTLVILCTLLT	DNAJC5G	121	Q8N7S2
CASPVLTAVCLRWVL	ESPL1	1151	Q14674
WIAVSALCSSSCPLL	KDM2B	1161	Q8NHM5
VLVLCLSCLLLLSIW	CYP2C19	6	P33261
WTTILCIAIGCSLLQ	GPRC5D	126	Q9NZD1
CLLFWAVLVTATLCT	FGFR1	6	P11362
CILALVCWITVFLLQ	IGFL3	6	Q6UXB1
ALILTACIIWCICSI	CPD	1311	O75976
TAWCCILGLISVALT	HGSNAT	536	Q68CP4
ELWALCLACLRALQT	KNDC1	461	Q76NI1
AALLLWIVSSCLCRA	CNTNAP2	11	Q9UHC6
ALVLCLSCLFLLSLW	CYP2C18	6	P33260
VLVLCLSCLLLLSLW	CYP2C9	6	P11712
NVLLFSTLDSIWCCI	CFAP69	581	A5D8W1
AAALCLCSLLLWPTR	MFSD12	456	Q6NUT3
LLLLQVCWLQCAASE	CDH3	11	P22223
LVCVAVWLAVTTQCL	P2RY6	146	Q15077
FLVVAILAVCLLCWT	NPBWR1	251	P48145
PLLSSVLTVAWICCL	JAG1	1071	P78504
IQACCSLALSTWLLS	RNF150	6	Q9ULK6
LRWCLLQLAITDTCA	SLC22A10	176	Q63ZE4
ILIPCWCSLVCLSRI	SGPP1	236	Q9BX95
KDCLVLVWSLCSVLQ	WDR18	141	Q9BV38
VAWLIFLCVVLCVSS	MRGPRX4	181	Q96LA9
NLCLCLLLAWVIVFL	SLC6A7	216	Q99884
LAFCIWIVASSLILL	PIGW	371	Q7Z7B1
SVLACEILWDLPCSI	SCMH1	6	Q96GD3
SLFVWVLVNTACCVL	AMFR	81	Q9UKV5
CLLCIVVLVATELWT	CLCC1	191	Q96S66
SAISCLCVWIITSVE	SPG11	1481	Q96JI7
SWVSTLIKCLPIFCL	TMEM86A	36	Q8N2M4
STCWCRSLVLVCVLA	TMEM64	116	Q6YI46
LCTWLNRCGATTLIV	TMTC1	431	Q8IUR5
FFLQTLLWILCATVC	MMP16	21	P51512
VLVVLSWVLCLCVFS	SLC52A1	376	Q9NWF4
CWLLSVVGIFCILLA	SGMS1	311	Q86VZ5
LRVALCLLCWTPAAV	TMEM87B	26	Q96K49
DSRLWACILLSCLLS	SLC35E4	251	Q6ICL7
SVLACLLVLALAWVS	TMUB1	16	Q9BVT8
TLTCTCVAATLFWLL	FLT1	761	P17948
VLLSAVLWCLTGVQC	ZPBP2	6	Q6X784